Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Buy” by Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have received an average rating of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $43.17.

A number of research firms have recently commented on ORKA. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Thursday, October 31st. Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th. Wedbush started coverage on Oruka Therapeutics in a research note on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Lifesci Capital started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective on the stock. Finally, Stifel Nicolaus started coverage on Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $27.64 on Thursday. Oruka Therapeutics has a 1 year low of $18.72 and a 1 year high of $53.88. The company’s 50 day moving average is $26.88. The stock has a market capitalization of $33.44 million, a P/E ratio of -4.60 and a beta of 0.87.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.